European Archives - Page 398 of 1317 - European Medical Journal

Platinum Resistance in Ovarian Cancer

Approximately 80% of females with ovarian cancer are diagnosed with advanced disease (International Federation of Gynecology and…

From Podium into Practice: Working Together to Revolutionise Cancer Care in the Real World

Cancer is on course to be the leading cause of death in the EU by 2035. Europe’s population is ageing rapidly, and obesity rates continue…

Novel Approaches to Treat Glioblastoma Multiforme

Glioblastoma multiforme (GBM), central nervous system (CNS) WHO Grade 4 astrocytoma, is an almost uniformly lethal disease…

Comparison of Breast Sensibility Following Breast Reconstruction with Two Different Techniques

Breast cancer is the most common cancer worldwide, accounting for 12.5% of all new cancer cases per year.1 According to the Spanish…

BRCA Mutation in Ovarian Cancer: Implications for Screening, Diagnosis, and Preventive Measures

Ovarian cancer is a serious type of cancer that affects women. It has high morbidity and mortality and is the seventh biggest cause of…

10-Year Follow-Up of MammaPrint Prognostic Assay in Early Breast Cancer: A German Registry Study

In modern oncology, the utilisation of gene expression assays has driven the development of personalised treatment strategies for patients…

Congenital Dermatofibrosarcoma Presenting as an Atrophic Plaque

Dermatofibrosarcoma protuberans (DFSP) is a rare, locally aggressive sarcoma that most commonly occurs on the trunk of patients…

Effectiveness of Vinorelbine in the Management of Pseudomyogenic Hemangioendothelioma: A Case Report

Pseudomyogenic hemangioendothelioma (PMH) is an uncommon vascular tumour with challenges often in its diagnosis and treatment…

Ependymoma Alongside Hereditary Paraganglioma-Phaeochromocytoma Syndrome Due to a SDHB Mutation: A Case Report 

Succinate dehydrogenase (SDH) is a mitochondrial enzyme with a role in both the Krebs cycle and the electron transport chain…

TAVR Outcomes: Insights From the STS/ACC TVT Registry

Researchers have found a modest increase in risk-adjusted 30-day mortality rates following transcatheter aortic valve replacement (TAVR) between 2019 and 2022.